Precious Metals

[gfp927z]

Blade, >> CEMP <<


Looks like Murphy's Law strikes again. I had a tiny position but sold a couple weeks ago after doing more research. Solithromycin should still get approved, but the manufacturing issues will probably mean a year delay.

They should have just produced it here in the US instead of India and Mexico, a little more expensive but would have avoided this costly delay. Now CEMP may have to do an unfavorable financing. Could look at the stock again in 2017 after the situation becomes clearer.

Biotech isn't the only risky sector, even the food/beverage area can be treacherous (FLO and REED). Landmines everywhere, and after almost 8 years of bull market you wonder when the next financial crisis will hit. Over the past 2 years I mainly went into physical gold/silver.